Shandong Xinbo is a research service enterprise integrating pharmacodynamic research, toxicological research, drug analysis and testing services, animal pathology testing, and medical device evaluation services. It is a high-tech enterprise, a Shandong Provincial Enterprise Technology Center, and a Shandong Provincial Gazelle Enterprise.

Shandong Xinbo has established Jinan Laboratory and Linyi Laboratory. Currently, it has built nearly 20,000 square meters of pharmacology and toxicology research laboratories that meet international standards, equipped with over 800 advanced instruments and equipment from both domestic and international sources. The toxicology research laboratory is capable of conducting single-dose toxicity tests, repeated-dose toxicity tests, safety pharmacology tests, reproductive toxicity tests, genetic toxicity tests, local toxicity tests, immunogenicity tests, and toxicokinetic tests in accordance with the GLP standards of NMPA and FDA.

The company is dedicated to providing high-quality commissioned research services to new drug and medical research institutions. Since its establishment in 2010, it has provided over 12,000 services to more than 620 pharmaceutical companies, new drug research institutions, and scientific research institutes both domestically and internationally. It has completed nearly 540 preclinical evaluation services for innovative drugs in accordance with domestic and international regulatory requirements, including small molecule drugs, biological macromolecule drugs, new preventive and therapeutic vaccines, and Chinese medicine/natural medicine evaluations. It has assisted research and development units in obtaining over 100 new drug clinical approvals, and has also accumulated rich experience in the evaluation of therapeutic vaccines, cell and gene therapy drugs, which have developed rapidly in recent years. It has completed the evaluation of nearly 4,800 varieties of generic drugs.

In addition, the company continuously innovates and breaks through barriers, making improvements and explorations in areas such as challenging drug administration techniques for young animals, continuous intravenous drug administration, and tracheal drug administration. These advancements have been seamlessly integrated into safety evaluations. The company also pays close attention to the needs of innovative development in the global pharmaceutical industry. Focusing on the critical aspects of innovative drug research and development, and leveraging the experience accumulated from serving the domestic and international pharmaceutical industry, the company provides comprehensive preclinical research and development services for new drugs to the global pharmaceutical industry.